B. Carpiniello, M.G. Carta - Vol. 10, June 2004, Issue 2
Testo Immagini Bibliografia Summary Indice
Qualità di vita e depressione: problemi
metodologici ed impatto dei trattamenti
Quality of life and depression: methodological problems and impact
of treatments
1 Katschning H. How useful is the concept of quality of life in psychiatry. In: Katschnig H, Freeman H, Sartorius N, eds. Quality of life in mental disorders. Chichester: Wiley 1997:3-16.
2 Sederer LI, Dickey B, Hermann RC. The imperative of outcomes assessment in Psychiatry. In: Sederer LI, Dickey B, eds. Outcome Assessment in Clinical Practice. Baltimore: William & Wilkins 1996, pp. 1-8.
3 Pukrop R. Subjective quality of life. Critical look at a modern construct. Nervenartz 2003;74:48-54.
4 Zautra A, Goodhart D. Quality of life indicators: a review of literature. Comm Ment Health Rev 1979;4:1-10.
5 Katschning H, Angemeyer MS. Qualiyty of life in Depression. In: Katschning H, Freeman H, Sartorius N, eds. Quality of life in mental disorders. Chichester: Wiley 1997, pp. 137-148.
6 Orley J, Saxena S, Herrman H. Quality of life and mental illness. Br J Psychiatry 1998;172:291-3.
7 Corten P, Mercier C, Pelc I. Subjective quality of life: clinical model of assessment of rehabilitation treatment in psychiatry. Soc Psych Psychiat Epidemol 1994;29/4:178-83.
8 Andrews FM, Withey SB. Social indicators of Well-Being. New York: Plenum Press 1976.
9 Campbell A. Subjective measures of Well-Being. Am Psychologists 1976;31:117-24.
10 Levi L, Anderson L. Psychosocial stress:population, environment and the quality of life Spectrum. NY: Hollyswood 1975.
11 Beck AT. Cognitive Therapy and Emotional Disorders. New York: International University Press 1976.
12 Blackburn IM, Jones S, Lewin RJP. Cognitive style in Depression. Brit J Clin Psychol 1986;25:241-51.
13 Lehman AF. A Quality of Life interview for the chronically mentally ill. Eval Progr Plann 1988;11:51-62.
14 Simpson CJ, Hyde CE, Faragher EB. The chronically mentally ill in community facilities. A study of quality of life. Brit J Psych 1989;154:77-82.
15 Levitt AJ, Hogan TP, Bucowsky CM. Quality of life in chronic mentally ill patients in day treatment. Psychol Med 1990;20:703-10.
16 Sullivan G, Wells KK, Leake B. Clinical factors associated with better quality of life in a seriously mentally ill population. Hosp Comm Psych 1992;43:794-8.
17 Ruggeri M, Santolini N, Stegagno M, Imperadore G, Dall’Agnola RB. La qualità di vita dei pazienti psichiatrici. Epidemiologia e Psichiatria Sociale 1999;8(Suppl 1).
18 Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharm Bull 1993;2972:321-6.
19 Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Pol 1992;22/3:307-19.
20 Hunt SM, McKenna SP. A new measure of quality of life in depression: testing the reliability and construct validity of the QLSD. Health Pol 1992;22/3:321-30.
21 Stocker MJ, Dunbar GC, Beaumont G. The SmithKline Beecham Quality of Life Scale: a validation and reliability study in patients with affective disorders. Qual Life Res 1992;1/6:385-95.
22 Corrigan PW, Buican B. The construct validity of subjective quality of life for the severely mentally ill. J Nerv Ment Dis 1995;183:281-5.
23 Carpiniello B, Baita A, Rudas N. Evaluating subjective quality of life among psychiatric patients: Italian version of The Satisfaction with Life Domains Scale. It J Psych Behav Sci 1997;2:73-9.
24 Carpiniello B, Lai G, Pariante CM, Carta MG, Rudas N. Symptoms, standards of living, subjective quality of life. A Comparative study of schizophrenics and depressed outpatients. Acta Psych Scand 1997;96:235-41.
25 Judd LL, Rapaport MA, Paulus MP, Brown JL. Subsyndromal symptomatic depression (SSD): a new mood disorder? J Clin Psychiatry 1994;55:18S-28S.
26 Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depression. J Affect Disord 1997;167:6-10.
27 Tranter R, O’Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-7.
28 Simon GE. Social and economic burden of mood disorders. Biol Psychiatry 2003;64:208-15.
29 Hirschfeld RMA, Montgomery SA, Keller MB, Kasper S, Schatzeberg AF, Moller HJ, et al. Social functioning in Depression: a review. J Clin Psychiatry 2000;61:268-75.
30 Murray CJL, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from disease. Injuries and Risk Factors in 1990 and projected to 2020. Boston: Mass, Harvard University Press 1998.
31 Wells KB, Stewart A, Hays RD, Burnam A, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-9.
32 Ormel J, Von Korff M, Van den Brink W, Katon W, Brilman E, Oldehinkel T. Depression, anxiety and social disability show synchrony of change in primary care patients. Am J Public Health 1993;83:385-90.
33 Berardi D, Berti Ceroni G, Leggieri G, Rucci P, Ustun B, Ferrari G. Mental, physical and functional status in primary care attenders. Int J Psychiatry Med 1999;29:133-48.
34 Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Koch WL, Grant I. Assessment of the quality of life of patients with major depression. Psychiatr Serv 1997;48:224-30.
35 Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Golshan S, Grant I. Preliminary longitudinal assessment of quality of life in patients with major depression. Psychopharmacol Bull 1997;33:23-9.
36 Rucci P, Gherardi S, Tansella M, Piccinelli M, Berardi D, Bisoffi G. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 2003;76:171-81.
37 Gupta S, Kulhara P, Vcerma SK. Quality of life in schizophrenia and dysthymia. Acta Psych Scand 1998;97:290-6.
38 Fruhwald S, Loffler H, Eher R, Saletu B, Baumhackl U. Relationship between depression, anxiety and quality of life: a study of stroke patients compared to chronic low back pain and myocardial ischemia patients. Psychopathology 2001;34:50-6.
39 Janssens AC, van Doorn PA, de Boer JB, Kalkers NF, van der Mech, Passchier J, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003;9:397-403.
40 Cramer JA, Blum D, Reed M, Fanning K, and Epilepsy Impact Project Group. The influence of comorbid depression on quality of life for patients with epilepsy. Epilepsy Behav 2003;4:515:21.
41 Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley Ma. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003;290:215-21.
42 Mechanic D, McAlpine D, Rosenfield S, Davis D. Effect of illness attribution and depression on the quality of life among person with serious mental illness. Soc Sci Med 1994;39/2:155-64.
43 Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in national survey. Int Clin Psychpharmacol 2000;15:319-28.
44 Masellis M, Rector NA, Richter MA. Quality of life in OCD: differential impact of obsessions, compulsions and depression comorbidity. Can J Psychiatry 2003;48:72-7.
45 Turner R. Quality of life: experience with sertraline. Int Clin Psychpharmacol 1994;9(Suppl 3):27-31.
46 Lonnqvist J, Sintonen H, Syvalahti E, Appelberg B, Koskinen T, Mannikko T, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psych Scand 1994;89:363-9.
47 Walker V, Streiner DL, Novosel S, Rocchi A, Levine MA, Dean MD. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol 1995;15(Suppl 2):60S-67S.
48 Heilingestien JH, Ware JE jr, Beusterien KM, Roback PJ, Abdreas j, Tollefson GD. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr 1995;7(Suppl):125-37.
49 Lonnqvist J, Sihvo S, Syvhalahti E, Sintonen H, Kiviruusu O, Pitkanen E. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psych Scnad 1995;91:189-94.
50 Partonen T, Lonqvist J. Moclobemide and fluoxetine in the treatment of seasonal affective disorder. J Affect Disord 1996;41:93-9.
51 Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux BP, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psych Scand 1996;94:205-10.
52 Brion S, Audrain S, de Bodinat C. Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin. Presse Med 1996;25:461-8.
53 Kosics JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein I, et al. Double-blind comparison of sertraline, imipramine and placebo in the treatment of dysthymia: psycosocial outcomes. Am J Psychiatry 1997;154:390-5.
54 Holland JC, Romano SJ, Heilingstien JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychoncology 1998;7:291-300.
55 Wheatley DP, van Moffaert M, Timmermann L, Cremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe Major depressive episode. The Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998;59:306-12.
56 Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in primary care setting in France. Pharmacoeconomics 1998;13:157-69.
57 Sogaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999;13:406-14.
58 Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999;319:1534-8.
59 Sechter D, Troy S, Peternetti S, Boyer P. A double-blind comparison of sertraline on fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999;14:41-8.
60 Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group, Int Clin Psychopharmacol 1999;14:329-37.
61 Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999;56:932-9.
62 Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 years and older. Int Psychogeriatr 1999;11:85-99.
63 Simon GE, Hieligstein J, Revicki D, vonKorff M, Katon WJ, Ludman E, et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Fam Med 1999;8:319-25.
64 Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairment. Am J Psychiatry 1999;156:1608-17.
65 Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double blind, placebo controlled trial in dystymic patients without major depression. J Clin Psychiatry 2000;61:821-7.
66 Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M, Smadja N, et al. Prevention of recurrent depressive episodes with minalcipram and consequences on quality of life. J Affect Disord 2000;58:171-80.
67 Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six month of continuous therapy. J Clin Psychopharmacol 2000;20:645-52.
68 Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatient. J Clin Psychiatry 2000;61:559-68.
69 Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar ED. Comparison of sertraline and nortriptyline in the treatment of major depressive episode in late life. Am J Psychiatry 2000;157:729-36.
70 Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-9.
71 Guelfi JD, Ansseau M, Timmermann L, Korsgaard M and Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21:425-31.
72 De Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dystymic disorder. J Psychother Pract Res 2001;10:117-23.
73 Russell JM, Koran LM, Rush J, Hirshfeld RM, Harrison W, Friedman ES, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27.
74 Doraiswamy PM, Khan ZM, Donahue RM, Richard NE. Quality of life in geriatric depression: a comparison of remitters, partial responders and nonresponders. Am J Geriatr Psychiatry 2001;9:423-8.
75 Kroenke K, West SL, Swindle R, Giselnan A, Eckert GJ, Dolor R, et al. Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care: a randomized trial. JAMA 2001;286:2947-55.
76 Barge-Schaapveld DQ, Nicolson NA. Effects of antidepressant therapy on the quality of life experience sampling study. J Clin Psychiatry 2002;63:477-85.
77 Detcke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90.
78 Kocsis JH, Schatzeberg A, Rush AJ, Klein DN, Howland R, Gniwesch D, et al. Psychosocial outcomes following long-term, double-blind, treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 2002;59:723-8.
79 Baca E, Gonzalez de Chavez M, Garcia-Toro M, Perez-Arnau F, Porras-Chavarrino A. Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:493-500.
80 Baca Baldomero E, Cervera Enguix S, Groupo de studio Teseo. Quality of life in depressed patients in primary care setting. Effectiveness and safety of venlafaxine extended release. Actas Esp Psiquiatr 2003;31:331-8.
81 Swenson GR, O’Connor CM, Barton D, Van Zyl LT, Swedberg K, Forman LM, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003 92:1271-6.
82 Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol-dependent patients with comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003;38:619-25.
83 Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of Venlafaxine for the long term treatment of chronic pain associated with major depressive disorder. Am J Ther 2003;10:318-23.
84 Russel J, Kornstein SG, Shea TM, McCullough JP, Harrison WM, Hirschfeld RMA, et al. Chronic depression and comorbid personality disorders: response to Sertraline versus Imipramine. J Clin Psychiatry 2003;64:554-61.
85 Kennedy SH, Eisfeld BS, Cooke RG. Quality of life: an important dimension in assessing the treatment of depression. J Psychiatry Neurosci 2001;26(Suppl):S23-8.
86 Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000;12(Suppl 1):95-101.
87 Pyne JM, Bullock D, Kaplan RM, Smith TL, Gillin JC, Golshan S, et al. Health-related quality of life measure enhances acute treatment response prediction in depressed inpatients. J Clin Psychiatry 2001;62:261-8.